Olanzapine vs. haloperidol in the treatment of elderly chronic schizophrenia patients

The impact upon extra‐pyramidal side effects, clinical symptoms and quality of life of a switch from conventional to atypical antipsychotics (risperidone or olanzapine) in elderly patients with schizophrenia

“…Furthermore, improvement may have been due to involvement in the trial rather than being associated with the medication changes. However, the magnitude and direction of changes in both clinical and EPSE scales are consistent with the atypical arm of previous double-blind studies (Jeste et al, 2001;Barak et al, 2001, Maguire et al, 2001. These patients were recruited to the study when both drugs were freely available and commonly used in Australia for schizophrenia.…”

“…However, these studies are imperfect for several reasons including: heterogeneous study population (Madhusoodanan et al, 1995;Joshi and Joshi, 1996;Davidson et al, 2000;Madhusoodanan et al, 2000), retrospective design (Kiraly et al, 1998;Madhusoodanan et al, 1999a;Solomon and Geiger, 2000) single arm (Madhusoodanan et al, 1995;Berman et al, 1996;Madhusoodanan et al, 1999b;Davidson et al, 2000;Madhusoodanan et al, 2000;Solomons and Geiger, 2000) small sample size (Madhusoodanan et al, 1995;Berman et al, 1996;Barak et al, 2001;Madhusoodanan et al, 2000) nonspecific or limited outcome measures (Kiraly et al, 1998) and short follow up period (Madhusoodanan et al, 1999b;Maguire et al, 2001;Jeste et al, 2001). Despite these limitations they have consistently indicated efficacy in improving core schizophrenic symptoms, reducing extra pyramidal side effects (EPSE) and being well tolerated.…”

Prise en soins de la schizophrénie chez la personne âgée

“…Les effets de l'olanzapine et de l'halopéridol avaient été c omparés chez 20 patients âgés souffrant d'une exacerbation de leur schizophrénie de longue date malgré un traitement par neuroleptiques typiques [23]. Leur traitement p sychotrope en cours avait été stoppé 48 heures avant l'inclusion dans l'étude et les patients répartis en un groupe traité par olanzapine et un autre traité par halopéridol.…”

A comparison of the efficacy and safety of olanzapine and risperidone in the treatment of elderly patients with schizophrenia: an open study of six months duration

“…However, these studies are imperfect for several reasons including: heterogeneous study population (Madhusoodanan et al, 1995;Joshi and Joshi, 1996;Davidson et al, 2000;Madhusoodanan et al, 2000), retrospective (Kiraly et al, 1998;Madhusoodanan et al, 1999a;Solomon and Geiger, 2000) and single arm design (Madhusoodanan et al, 1995b;Berman et al, 1996;Madhusoodanan et al, 1999b;Davidson et al, 2000;Madhusoodanan et al, 2000;Solomons and Geiger, 2000). Small sample size (Madhusoodanan et al, 1995;Berman et al, 1996;Madhusoodanan et al, 2000;Barak et al, 2002), the use of non-specific or limited outcome measures (Kiraly et al, 1998) and short follow-up period (Madhusoodanan et al, 1999b;Kennedy et al, 2003;Jeste et al, 2003) have further limited the impact of their findings. Despite these limitations they have consistently indicated efficacy in improving core schizophrenic symptoms and reducing extra pyramidal side effects (EPSE) while concurrently being well tolerated.…”

“…Despite these limitations they have consistently indicated efficacy in improving core schizophrenic symptoms and reducing extra pyramidal side effects (EPSE) while concurrently being well tolerated. More recent studies have compared olanzapine with haloperidol in both open label (Barak et al, 2002) and double blind conditions (Kennedy et al, 2003) with both studies reporting superior efficacy and a reduction in motor side-effects. Jeste et al (2003) reported on a large, multicentre study comparing olanzapine with risperidone over 8 weeks under double-blind conditions.…”